DRAKO Non-interventional Study
Research type
Research Study
Full title
DRAKO-An observational study to assess the effectiveness of intravitreal aflibercept in routine clinical practice in patients with visual impairment due to diabetic macular oedema(DMO)
IRAS ID
183403
Contact name
Sobha Sivaprasad
Contact email
Sponsor organisation
Bayer Plc
Duration of Study in the UK
3 years, 0 months, 2 days
Research summary
The purpose of this observational study is to obtain information on how effective aflibercept (Eylea®) is in real life clinical settings and how it is actually being used in clinics. Aflibercept is already licensed (approved by the UK medicines regulatory authority).
The study will involve approximately 750 patients who are undergoing aflibercept treatment for Diabetic Macular Oedema (DMO) in approximately 30 study centres located throughout the United Kingdom.REC name
North West - Liverpool Central Research Ethics Committee
REC reference
16/NW/0238
Date of REC Opinion
23 Mar 2016
REC opinion
Favourable Opinion